Related Experiment Video

Updated: May 31, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model

Xu Wang1, Jun Li, Yuxiang Wang

  • 1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.

ACS Nano
|July 7, 2011
PubMed

Insights

This study shows a new nanoparticle drug delivery system effectively overcomes chemotherapy resistance in cancer cells. The targeted nanoparticle enhances drug retention, improving treatment efficacy against resistant tumors.

Area of Science:

  • Nanomedicine
  • Cancer Biology
  • Drug Delivery

Background:

  • Chemotherapy resistance, particularly P-glycoprotein (P-gp)-mediated resistance, is a significant challenge in cancer treatment.
  • Paclitaxel is a widely used chemotherapeutic agent but its efficacy is limited by P-gp efflux pumps.
  • Targeted drug delivery systems offer a promising strategy to overcome drug resistance and improve therapeutic outcomes.

Purpose of the Study:

  • To evaluate a novel folate receptor-targeted nanoparticle (HFT-T) for overcoming paclitaxel resistance.
  • To investigate the mechanisms underlying the nanoparticle's efficacy in P-gp-overexpressing cancer models.
  • To assess the in vitro and in vivo performance of HFT-T compared to free paclitaxel and non-targeted nanoparticles.

Main Methods:

  • Synthesis and characterization of the heparin-folate-paclitaxel (HFT-T) nanoparticle.
  • In vitro studies using P-gp-overexpressing cancer cells (KB-8-5) to assess cellular uptake, retention, and antiproliferative activity.
  • In vivo studies using a KB-8-5 xenograft model to evaluate tumor targeting, drug retention, and therapeutic efficacy.
  • Immunohistochemical analysis to investigate mechanisms of action, including microtubule stabilization and proliferation inhibition.

Main Results:

  • HFT-T nanoparticles demonstrated superior inhibition of proliferation in P-gp-overexpressing cancer cells compared to free paclitaxel or non-targeted nanoparticles.
  • Enhanced cellular uptake and prolonged intracellular retention of paclitaxel were observed with HFT-T.
  • In vivo studies showed improved paclitaxel delivery and retention in tumor tissues, leading to significant tumor growth retardation.
  • HFT-T treatment was associated with increased microtubule stabilization, mitotic arrest, and antiangiogenic activity.

Conclusions:

  • The folate receptor-targeted HFT-T nanoparticle effectively enhances cellular accumulation and retention of paclitaxel in P-gp-overexpressing cancer cells.
  • HFT-T nanoparticles show significant potential in overcoming P-gp-mediated chemotherapy resistance and improving therapeutic efficacy.
  • Targeted nanomedicine approaches represent a promising strategy for enhancing the treatment of drug-resistant cancers.

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...